Congress Raises Concerns Over High Medicine Prices and Patent Law Use in India
Congress leader Jairam Ramesh criticized the Modi government for high medicine prices in India, citing inspections revealing large gaps between procurement costs and retail prices in hospitals, including a Polymyxin-B injection sold at 67 times its cost. He highlighted the financial burden on patients, especially for life-threatening diseases like cancer, and questioned why legal provisions allowing government use of patented drugs have not eased access. The Kerala High Court ruling supporting such measures was also referenced.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. Coverage leans left-leaning overall (Left 61%, Centre 39%, Right 0%). Overall sentiment is negative (28/100). Lens Score 68/100.
Outlets measured: thestatesman, theprint, thetelegraph. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 3 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (28–28/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetelegraph broke this story on 5 Oct, 10:05 am. Other outlets followed.